BioWorld

July 18, 2005

Chiron's Pulminiq 'Approvable,' But Flu Vaccine Trouble Arises

After to a split advisory committee vote last month on Chiron Corp.'s Pulminiq, the FDA issued an approvable letter but asked for another study to confirm efficacy of the lung transplant drug. (BioWorld Today) Read More

Adherex Could Get $220M In Cancer Deal With GSK

BrainCells' Neurogenesis Work Brings In $17.7M In First Round

To Keep Biodefense Issues In Focus, Be 'Involved Politically'

Trading Heavy As Momenta's Stock Price Jumps Once Again

Other News To Note

Appointments And Advancements

NIH changes set industry up for workforce, ideas drought

BioWorld

On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...

Today's news in brief

BioWorld

BioWorld briefs for March 6, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for March 6, 2025

Roche looks to grow with sequencing by expansion tech

BioWorld MedTech

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that rival Illumina Inc. could face a real run...

Illustration of Magnet Biomedicine's Trueglue platform

Magnet, Eli Lilly sign $1.25B molecular glue deal for oncology

BioWorld

About 17 months after emerging from stealth with its Trueglue discovery platform, Magnet Biomedicine Inc. has joined with Eli Lilly and Co. to discover, develop...